- Home
- FWRG vs OCS Comparison
FWRG vs OCS Comparison
Compare FWRG & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FWRG | OCS |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 768.7M | 732.4M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FWRG | OCS |
|---|---|---|
| Price | $10.23 | $8.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $19.50 | ★ $36.37 |
| AVG Volume (30 Days) | ★ 1.0M | 183.9K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,222,501,000.00 | N/A |
| Revenue This Year | $13.60 | N/A |
| Revenue Next Year | $11.67 | $365.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.34 | N/A |
| 52 Week Low | $9.88 | $9.00 |
| 52 Week High | $18.82 | $34.48 |
Technical Indicators
Market Signals| Indicator | FWRG | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 35.18 | 28.67 |
| Support Level | $10.03 | N/A |
| Resistance Level | $13.47 | $10.84 |
| Average True Range (ATR) | 0.42 | 0.49 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 18.45 | 9.78 |
Price Performance
Historical ComparisonAbout FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. The company generates revenues from Restaurant sales and Franchise revenues. It generates maximum revenue from Restaurant sales.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.